Arboreal Bioinnovations raises ₹230 crore Series A to scale specialty food ingredients
The round, co-led by EAAA Alternatives and Omnivore, will fund manufacturing, R&D and commercialisation of functional food ingredients for Indian consumer brands and nutraceutical makers.
What happened
Arboreal Bioinnovations raised ₹230 crore in a Series A co-led by EAAA Alternatives and Omnivore to expand manufacturing, R&D and commercialisation of
Key facts
- ₹230 crore
- over 300 product launches
- more than 1,100 consumer brands and nutraceutical manufacturers
- 18 months
- doubled year-on-year growth
Why this matters
Consumer-health, food and nutraceutical companies should view Arboreal’s expansion as a potential partnership or strategic-sourcing opportunity for differentiated functional formulations.
What to watch
- Announcement of new plant location, capacity, commissioning timeline and product categories.
- Named supply contracts or co-development partnerships with major FMCG, D2C nutrition or nutraceutical brands.
- Evidence of import substitution through pricing, lead-time or local-sourcing claims.
- New product launches in protein, fibre, probiotics/prebiotics, natural sweetening, fortification or clean-label ingredient segments.
- Regulatory approvals, export certifications and entry into overseas markets.
- Follow-on funding, strategic investment or acquisition activity among Indian specialty-ingredient companies.
- Commission or expand domestic production lines for high-volume functional ingredient categories.
- Build application labs and co-development teams serving food, beverage and nutraceutical customers.
- Prioritise long-term supply agreements with anchor consumer-brand clients.
- Use R&D funding to develop India-specific formulations around affordability, taste masking, fortification and clean-label claims.
- Pursue regulatory, quality and traceability certifications needed for larger FMCG and export accounts.